Detalhe da pesquisa
1.
Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).
Mol Psychiatry
; 25(7): 1604, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30617276
2.
Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).
Mol Psychiatry
; 25(7): 1592-1603, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30283029
3.
Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder.
J Clin Psychopharmacol
; 40(3): 287-292, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32332464
4.
Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression.
Ann Clin Psychiatry
; 32(4): 18-26, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33125454
5.
Efficacy and Tolerability of Adjunctive Intravenous Sodium Nitroprusside Treatment for Outpatients With Schizophrenia: A Randomized Clinical Trial.
JAMA Psychiatry
; 76(7): 691-699, 2019 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30916714
6.
Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression.
J Psychiatr Res
; 110: 166-171, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30641350